2024
Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity
Lensch V, Gabba A, Hincapie R, Bhagchandani S, Basak A, Alam M, Noble J, Irvine D, Shalek A, Johnson J, Finn M, Kiessling L. Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity. ACS Nano 2024, 18: 26770-26783. PMID: 39283240, DOI: 10.1021/acsnano.4c07360.Peer-Reviewed Original ResearchCellular immunityDendritic cellsToll-like receptorsVirus-like particlesCD8<sup>+</sup> T cellsTumor-specific cellular immunityVaccine developmentCancer vaccine developmentInfiltrate solid tumorsMurine melanoma modelT cell functionInhibited tumor growthActivate TLR signalingTumor controlCancer immunotherapyCD4<sup>+</sup>Melanoma modelTLR7 agonistDC activationT cellsSolid tumorsTumor cellsTumor growthHumoral immunityVLP platform
2023
Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation
Bhagchandani S, Vohidov F, Milling L, Tong E, Brown C, Ramseier M, Liu B, Fessenden T, Nguyen H, Kiel G, Won L, Langer R, Spranger S, Shalek A, Irvine D, Johnson J. Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. Science Advances 2023, 9: eadg2239. PMID: 37075115, PMCID: PMC10115420, DOI: 10.1126/sciadv.adg2239.Peer-Reviewed Original ResearchConceptsToll-like receptor 7Cancer immunotherapyImmune stimulationMouse syngeneic tumor modelsNext-generation cancer immunotherapyImmune-related toxicitiesAcute systemic inflammationInnate immune cellsSyngeneic tumor modelsPotential cancer immunotherapySystemic inflammationImmune cellsReceptor 7Systemic administrationIntravenous administrationMyeloid cellsTumor growthSystemic toxicityTumor modelObservable systemic toxicityPotent stimulationImidazoquinolinesImmunotherapyStimulationProdrug